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“The time of ad hoc angioplasty for the patient with 
multivessel coronary artery disease has passed.” James 
Wilson, Texas Heart Institute. 
 
Abstract 
The practice of percutaneous coronary intervention 
has overtaken coronary bypass surgery in the treatment 
of ischaemic heart disease. Several randomized 
controlled as well as registry and observational trials 
have addressed the issue of patient selection and 
outcomes in order to provide the cardiologist with data 
enabling optimal treatment selection. This article 
reviews the major trials performed over the past 25 
years, underscoring their strengths and limitations and 
draws on lessons and guidelines that are relevant to our 
local practice. 
 
Introduction 
Coronary artery bypass grafting (CABG) was 
popularised in the 1970’s. Within a decade this 
operation became the commonest and most 
comprehensively studied major surgical procedure in the 
Western world. Randomised trials proved that, in certain 
subsets of patients, it was superior to medical treatment. 
A third treatment modality, that of percutaneous 
coronary intervention (PCI), initially with balloon 
angioplasty and later with stent implantation, has 
captured an increasing share of the market over the past 
25 years, such that the current volume of PCI has far 
outstripped surgery. This situation has fuelled intense 
debate as to which treatment best serves the patient with 
severe coronary artery disease. Numerous trials have 
been conducted, comparing PCI with CABG, and these 
have resulted in guidelines, reached by consensus 
amongst the European Societies of interventional 
cardiologists and cardiac surgeons, defining the optimal 
treatment for these patients. 
This paper describes these developments, analyses 
the local situation, and asks whether guidelines are being 
adhered to in the interest of best practice. 
 
Key Words 
Ischaemic heart disease, multivessel disease, coronary 
surgery, percutaneous intervention 
 
CABG versus medical therapy 
In 1994 the Lancet published a meta-analysis of 
seven randomised trials of CABG versus medical 
treatment, analysing 2650 patients with a follow-up of 
ten years.1 The authors showed there was a survival 
advantage and marked symptom improvement with 
CABG as compared with medical therapy in left main 
stem (LMS) disease, triple vessel disease (3VD) and 
proximal left anterior descending (LAD) disease. These 
benefits were enhanced with severe symptoms, a 
positive stress test and impaired ejection fraction (EF). 
The results were analysed on an intention-to-treat basis 
although 40% of patients assigned to medical treatment 
crossed over to surgery. Only 10% of patients received a 
left internal thoracic artery (LITA) graft, known to be an 
important component of surgery. There was no survival 
value in CABG for single or double vessel disease and 
normal LV function. The authors concluded that future 
trials comparing CABG with another treatment should 
include a high proportion of patients in whom surgery is 
known to be beneficial. However this never happened. 
 
CABG versus PCI 
Randomised controlled trials 
From 1994 to 2002 five major randomised 
controlled trials of CABG versus PCI were conducted, 
namely the Randomised Intervention Treatment of 
Angina (RITA),2 the Coronary Angioplasty versus 
Bypass Revascularisation Investigation (CABRI),3 the 
German Angioplasty Bypass Surgery Investigation 
(GABI),4 the Bypass Angioplasty Revascularisation 
Investigation (BARI),5 and the Stent or Surgery trial 
(SoS).6 None of the patients selected in these trials had 
LMS disease and EF was either normal or not specified. 
From an initial combined population exceeding 100,000, 
patient selection resulted in only 5% entering these trials 
(range 3-12% for individual trials). The resultant 
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samples were unrepresentative of the real world CABG 
population where LMS disease is present in over 20% 
and low EF in over 35%. The incidence of 3VD in the 
studies was a mean of 31%, that of proximal LAD 
disease was either low or unspecified and LITA usage 
was 75% (all parameters over 90% in the real CABG 
world).7 In summary the vast majority of these patients 
had single or double vessel disease and normal LV 
function, a population in whom there was no expected 
prognostic benefit from surgery. Conversely these trials 
largely excluded those patients who are known to benefit 
prognostically from surgery, namely those with LMS 
disease and 3VD, those with proximal LAD disease and 
impaired EF. 
A meta-analysis of 5 trials comparing CABG and 
PCI also excluded patients with LMS disease and 
impaired EF. Patients selected in these trials represented 
2 to 5% (depending on the particular trial) of the initial 
population. The overall incidence of 3VD was 42%.8 
The Arterial Revascularisation Therapy Study, ARTS, 
one of these five trials, included 68% of patients with 
single or double vessel disease, and all patients had 
normal LV function. The authors reported similar one 
and five-year survival rates for surgery and PCI. 
However, reintervention rates were 30% for PCI versus 
9% for CABG and mortality in a subset of 208 diabetics 
was 13% for PCI and 8% for CABG.9 The SoS trial, also 
included in this meta-analysis, reported a significantly 
higher one-year mortality in the PCI group (2.5 versus 
0.8%).6 The 6-year median follow-up confirmed a 
sustained significantly higher mortality of 10.9% for PCI 
versus 6.8% with CABG. 
David Taggart, a cardiac surgeon from Oxford, UK, 
highlighted the inherent prejudice of these papers 
against surgery in that they included highly selected 
patient populations unrepresentative of multi-vessel 
disease in the real CABG world. Moreover editorials 
disregarded this basic flaw.10 
 
Registry and observational trials 
A study by Hannan reported on long-term outcomes 
in almost 60,000 patients undergoing surgery or 
stenting.11 Data was derived from the New York 
Registry during a 3-year period 1997 to 2000 and 
reflected a real world situation. One-year mortality for 
all groups was 6% after CABG versus 9% after PCI. The 
mortality at 3 years in patients with 3VD was 10.7% 
after CABG and 15.6% after PCI. The hazard ratio for 
death at 3 years with CABG versus PCI was 0.76 for 2-
vessel disease and 0.65 for 3VD. The incidence of repeat 
revascularisation was 5% for CABG versus 35% for 
PCI. 
The Syntax trial is another landmark study 
comparing bypass and stenting in the real world.12 1800 
patients, in whom the cardiologist and surgeon 
determined to offer equivalent revascularisation, were 
randomised to receive CABG or PCI. From the original 
4337 patients 1262 were deemed ineligible, and a further 
1275, deemed only suitable for one treatment modality, 
were entered into the registry (1077 in the CABG arm 
and 198 in the PCI arm). At one year the two groups had 
similar rates of death from any cause. The rate of repeat 
revascularisation was significantly increased in the PCI 
group (13.5 versus 5.9%), as was the overall rate of 
major adverse cardiac and cerebrovascular events 
(MACCE) (17.8 versus 12.4%). The Syntax trial 
provided insight into the subgroups benefiting most 
from surgery by way of the Syntax score, an indicator of 
coronary disease severity and complexity. Thus the 
greatest difference in the MACCE rates was seen in the 
high Syntax score patients (≥32). At five years the 
overall rates of cardiac death (5.3 versus 9.0%), 
myocardial infarction (3.8 versus 9.7%), and 
reintervention (13.7 versus 25.9%), were significantly 
lower with CABG. The cumulative MACCE rate (25.8 
versus 36.0%) was also significantly lower after CABG 
in intermediate score (23-32) patients. At 5 years the 
registry patients showed an even larger divergence in the 
incidence of major events with 23% after CABG versus 
49% after PCI. The authors suggest that 71% of all 
patients, including 25% of patients of the original total 
in the CABG arm of the registry together with 46% of 
patients with Syntax scores above 22, are still best 
treated with CABG. For the remaining 29% of patients 
PCI is an alternative to surgery.  
The ASCERT trial, published in 2012, analyses the 
comparative-effectiveness of CABG and PCI and is not 
a randomised trial like the Syntax trial.13 Patients 
selected were over 65, without LMS disease, and 
requiring their first revascularisation. ASCERT 
represents over ten times as many patients as the total 
enrolment of all randomized trials comparing CABG 
and PCI (86,244 CABG and 103,549 PCI patients 
enrolled). This became possible because the Society of 
Thoracic Surgeons, the American College of 
Cardiology, and the Centres for Medicare and Medicaid 
Services pooled their data, sourced from the National 
Cardiovascular Data Registry and from the Society of 
Thoracic Surgeons Registry. This peri-procedural data, 
which was adjusted for risk, was combined with 
administrative data from the Medicare and Medicaid 
registries, providing records on long-term survival. The 
median follow-up was 2.7 years. Triple vessel disease 
was present in 80% of patients who underwent CABG 
and in 32% of patients undergoing PCI, confirming that 
treatment strategies were based on clinical grounds. The 
results at one year were similar, but over time the 
progressive survival advantage of CABG became 
significant. Survival at four years was 83.6% with 
CABG and 79.2% with PCI, the hazard ratio for death 
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was 0.79 and for combined stroke, death or MI was 0.81 
for CABG compared with PCI. The benefit from CABG 
was seen in all subgroups studied. The sheer numbers of 
patients in this study lend weight to the findings that 
survival was significantly better with CABG at four 
years, the results were consistent across all subgroups, 
and were consistent with the Syntax results, another 
large real word trial.  
 
Will stent revascularisation replace CABG? 
Lessons learnt from landmark trials 
Revascularization outcomes include three major 
endpoints, namely death, myocardial infarction, and 
symptom control (often requiring reintervention). With 
respect to death, surgical revascularization benefits 
patients who have severe multivessel disease and left 
ventricular dysfunction or other physiologic indicators 
of high risk. This evidence comes from three seminal 
trials performed in the 1970s and 1980s, namely the 
CASS randomised14 and registry15 trials and the 
Veterans trial,16 and from many observational studies. 
When angioplasty was introduced the hope was for a 
method of revascularization that would rival coronary 
artery bypass grafting.17 Angioplasty worked well in 
patients with no major risk factors, but failed in diabetic 
patients. The BARI trial demonstrated that the use of 
PCI in diabetics is potentially harmful when compared 
with a LITA to the LAD.5 In stable coronary disease the 
Courage trial, published in 2007, showed that the 
addition of PCI was unsuccessful in proving a positive 
impact over optimal medical therapy alone.18 The bare-
metal stent was developed as a metallic buttress to 
overcome restenosis after angioplasty. The use of stents 
drastically reduced the probability of emergent surgery 
after attempted PCI from 1 to 0.3%, increased 
angiographic success from 89 to 97%, increased 
freedom from six-month major events, from 77 to 85%, 
and drastically lowered six-month reintervention rate, 
from 20 to 8%.19  
The drug-eluting stent was developed to cure 
restenosis. However the probability of new lesion 
formation or late restenosis after intervention did not 
decrease. This figure was quoted as 10.1% restenosis 
requiring revascularisation during a three-year follow-up 
in the J-Cypher registry trial.20 Stent-in-stent repeat 
revascularisation was better than balloon angioplasty at 
preventing further revascularisation, with a hazard ratio 
of 0.44 favouring stenting, but two-year mortality was 
similar, at 10.4% after stent-in-stent and 10.8% after 
balloon angioplasty. Drug-eluting stents with their 
promise of no restenosis failed to deliver. 
 
Guidelines and local trends  
The current European Society of Cardiology/ 
European Association for Cardio-Thoracic Surgery 
(ESC/EACTS) guidelines are for a 1A recommendation 
for CABG in all patients with low predicted surgical 
mortality in all but one scenario, that of single or double 
vessel disease, not involving the proximal LAD. The 
other recommendation, at class 1C, is that, in patients 
with multivessel disease, the appropriate 
revascularization strategy should be discussed by the 
Heart Team.21 
CABG trends in the US showed a decline of 38% 
from a peak in the year 2001 to 2008. During the same 
period PCI decreased by 4%.22 During a corresponding 
7-year period locally, this time starting from peak 
CABG rates in 2004, the decline in CABG equates to 
49%. Local PCI rates increased by 63% during this same 
period and 26.5% of these were ad hoc procedures, 
where an investigational angiogram led directly to a 
PCI. In 2004, 463 patients were referred for CABG, of 
which 347 (75%) received 3 or more grafts for 
multivessel disease. In 2011 although the number of 
angiograms increased by 23% over the 2004 figure, only 
150 operations were performed for multivessel disease. 
Had referral patterns remained unchanged this figure 
would have reached 427. The real decline in referral of 
patients with multivessel disease for surgery over this 
period was of 277 patients in 2011, or 65% of the 
projected figure. Local PCI numbers increased from 520 
in 2004 to 845 in 2011, an increase of 62.5%. 
The SYNTAX score is a recognised, computer-
based tool for evaluating the risk of complications or 
failure after PCI. There are other risk stratification 
systems for estimating mortality after surgery. These 
estimates enable cardiologists to objectively advise 
patients regarding the revascularization method that has 
the best short- and long-term probability of success. In 
patients with non-life-threatening disease, those without 
significant LV dysfunction, 3VD or LMS disease, stent 
revascularization has become an alternative to surgery. 
However, this is true only if stenting is confined to 
patients whose anatomy is suited to it, a consideration 
that is well quantified in the SYNTAX score. With 
regard to the choice of revascularization, in a patient 
with multivessel disease, a reasoned approach must be 
taken, using these predictive tools and considering the 
patient's wishes. Treatment decisions should include all 
parties, the patient and the heart team, including the 
cardiologist and the cardiac surgeon. Thus the 
ESC/EACTS guidelines recommend that patients be 
adequately informed about the potential benefits and 
short- and long-term risks of a revascularization 
procedure and enough time should be allowed for 
informed decision making. This is a class 1C 
recommendation. In this setting there is virtually no 
recommendation for ad hoc angioplasty. 
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Inappropriate stenting 
Inappropriate stenting is a term that includes the 
placement of a coronary stent in a vessel when the lesion 
is not clinically important, as well as the placement of 
stents in patients who would benefit more from surgery. 
In a recent multicentre, prospective study the 
appropriateness of PCI was assessed in the acute and 
non-acute clinical scenario.23 500,154 PCI patients were 
recruited from 1091 US hospitals and these were 
classified as acute (71.1%) (ST-segment elevation MI 
20.6%, non-ST-segment MI 21.1% or instable angina 
29.3%) or non-acute (28.9%). In the acute group 98.6% 
were deemed appropriate. In the non-acute group 50.4% 
were deemed appropriate, 38% uncertain due to lack of 
adequate data, and 11.6% inappropriate. Appropriate 
PCI in the non-acute situation was defined as that 
performed in the presence of angina, high-risk ischaemia 
on stress testing, or optimal medical treatment. 95.8% of 
inappropriate PCI’s were performed in the absence of 
optimal medical treatment. Lack of adequate data in the 
patient’s file may be interpreted as a corresponding 
deficiency during the decision-making process leading 
to PCI, in which case the uncertain/inappropriate cohort 
reached a disturbing level of 49.6%. This study poses 
important implications on our local practice where non-
acute PCI’s represent 59.1% of the total program, more 
than twice that in the study by Chan. Moreover, because 
of long local PCI waiting times the patient’s clinical 
state may be unknown or may have changed from the 
time of referral to intervention. 
 
Conclusions 
Local referral patterns for multivessel disease have 
changed drastically over the years 2004-2011. During 
this period surgery for multivessel disease decreased by 
65% and PCI increased by 62.5%. Syntax scoring is not 
performed and treatment plans for patients with 
multivessel disease are not discussed in a 
multidisciplinary heart team, as proposed by 
ECS/EACTS guidelines. Ad hoc procedures, which 
allow little opportunity for informed consent, reached 
26.5%. The incidence of non-acute PCI is very high, a 
cohort in which the incidence of inappropriate stenting is 
increased. Clearly much can be improved. 
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